Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Giredestrant |
| Trade Name | Wilserdly |
| Synonyms | RG6171|GDC9545|GDC 9545|GDC-9545 |
| Drug Descriptions |
Wilserdly (giredestrant) is a selective estrogen receptor degrader (SERD) that prevents cell proliferation of ER-positive cells (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1023-1023). Wilserdly (giredestrant) in combination with Afinitor (everolimus) is FDA-approved for use in patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring ESR1 (ERalpha) mutations (FDA.gov). |
| DrugClasses | Hormone - Anti-estrogens 32 |
| CAS Registry Number | 1953133-47-5 |
| NCIT ID | C147030 |